Airdoc Technology ("Airdoc") was founded in September 2015. As a global market leader and pioneer in the field of AI-based retinal imaging, it endeavors to provide comprehensive and multi-faceted AI solutions for the early detection, auxiliary diagnosis and health risk assessment of chronic diseases. On November 5,2021, Airdoc was successfully listed on the Hong Kong and became the first HK-listed medical AI company.

 Airdoc's innovative SaMD product approved for the auxiliary diagnosis of diabetic retinopathy was the first of its kind to obtain the class III medical device certificate from the National Medical Products Administration of the PRC, and it has been launched into use in medical institutions for auxiliary diagnosis. In addition, in order to meet the underserved healthcare needs, Airdoc has also developed a variety of pipeline products based on AI-empowered retinal imaging technologies. These products are now widely used in different scenarios such as community clinics, health checkup centers, insurance companies, optometry centers and pharmacies for auxiliary diagnosis and health risk assessment purposes.